GigaGen, Inc.
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Inclusion Criteria: * Willing and able to provide informed consent. * Histologically or cytologically confirmed locally advanced or radiographically confirmed metastatic solid tumor malignancies ineligible for standard-of-care or refractory to or relapsing after at least one line of systemic therapy in the metastatic or advanced setting. * Measurable disease on imaging as based on Response Evaluation Criteria in RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. * Life expectancy greater than three months. * Electrocardiogram (ECG) without evidence of clinicall…
Administered by intravenous infusion
Administered by intravenous infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.